Molecular profiles of pyramidal neurons in the superior temporal cortex in schizophrenia.
Disrupted synchronized oscillatory firing of pyramidal neuronal networks in the cerebral cortex in the gamma frequency band (i.e., 30-100 Hz) mediates many of the cognitive deficits and symptoms of schizophrenia. In fact, the density of dendritic spines and the average somal area of pyramidal neurons in layer 3 of the cerebral cortex, which mediate both long-range (associational) and local (intrinsic) corticocortical connections, are decreased in subjects with this illness. To explore the molecular pathophysiology of pyramidal neuronal dysfunction, we extracted ribonucleic acid (RNA) from laser-captured pyramidal neurons from layer 3 of Brodmann's area 42 of the superior temporal gyrus (STG) from postmortem brains from schizophrenia and normal control subjects. We then profiled the messenger RNA (mRNA) expression of these neurons, using microarray technology. We identified 1331 mRNAs that were differentially expressed in schizophrenia, including genes that belong to the transforming growth factor beta (TGF-β) and the bone morphogenetic proteins (BMPs) signaling pathways. Disturbances of these signaling mechanisms may in part contribute to the altered expression of other genes found to be differentially expressed in this study, such as those that regulate extracellular matrix (ECM), apoptosis, and cytoskeletal and synaptic plasticity. In addition, we identified 10 microRNAs (miRNAs) that were differentially expressed in schizophrenia; enrichment analysis of their predicted gene targets revealed signaling pathways and gene networks that were found by microarray to be dysregulated, raising an interesting possibility that dysfunction of pyramidal neurons in schizophrenia may in part be mediated by a concerted dysregulation of gene network functions as a result of the altered expression of a relatively small number of miRNAs. Taken together, findings of this study provide a neurobiological framework within which specific hypotheses about the molecular mechanisms of pyramidal cell dysfunction in schizophrenia can be formulated.
Laboratory of Cellular Neuropathology , McLean Hospital, Belmont, Massachusetts , USA.
Charmaine Y
CY
Pietersen
Sarah A
SA
Mauney
Susie S
SS
Kim
Maribel P
MP
Lim
Robert J
RJ
Rooney
Jill M
JM
Goldstein
Tracey L
TL
Petryshen
Larry J
LJ
Seidman
Martha E
ME
Shenton
Robert W
RW
McCarley
Kai-C
KC
Sonntag
Tsung-Ung W
TU
Woo
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D017209:Apoptosis / Q000235:genetics; D019485:Bone Morphogenetic Proteins / Q000235:genetics / Q000378:metabolism; D003599:Cytoskeleton / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D005109:Extracellular Matrix / Q000235:genetics / Q000378:metabolism; D005260:Female; D020869:Gene Expression Profiling; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000235:genetics* / Q000378:metabolism*; D008875:Middle Aged; D017966:Pyramidal Cells / Q000378:metabolism*; D012559:Schizophrenia / Q000235:genetics* / Q000473:pathology*; D015398:Signal Transduction / Q000502:physiology; D013702:Temporal Lobe / Q000473:pathology*; D016212:Transforming Growth Factor beta / Q000235:genetics / Q000378:metabolism; D055815:Young Adult
D019485:Bone Morphogenetic Proteins; D035683:MicroRNAs; D016212:Transforming Growth Factor beta
cerebral cortex; gene expression profiling; laser-capture microdissection; microRNA; schizophrenia